With the success of the first clinical trials for brain chip implants, the neurotechnology sector has emerged as one of the most attractive investment markets of the current decade. Financial institutions estimate that the size of this emerging market could
exceed a hundred billion dollars by the end of the decade, as venture capital firms race to acquire stakes in startups specialized in this field. The economic viability of this technology is not limited to the medical aspect and treating
disabilities alone, but extends to include future applications in enhancing human cognitive abilities and integrating them with cloud computing interfaces. However, economic experts warn that the cost of these technologies in their early stages will be exorbitant, creating a challenge
regarding the commercial pricing model and the possibility of coverage by health insurance companies.
